Snake venom preparation for drug-resistant human immunodeficiency virus

Annals of Saudi Medicine

Volumn 28, Issue 4, 2008, Pages 292-293

  Alrajhi, Abdulrahman A ^a   Almohaizeie, Abdullah ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; AUTOIMMUNE 5; BIOVEN; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; SAMAYZ; SNAKE VENOM; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE MUTATION; GENOTYPE; HEMOPHILIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS RESISTANCE;

EID: 54349107474     PISSN: 02564947     EISSN: 13199226     Source Type: Journal    
DOI: 10.5144/0256-4947.2008.292     Document Type: Article

References (10)

1. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. DeGruttola V, Dix L, D'Aquila R, et al. The ralation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5:41-8.
3. Richman DD. Antiviral drug resistance. Antiviral Research 2006;71:117-21
4. Sen S, Tripathy SP, Patil AA, Chimanpure VM and Paranjape RS. High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. AIDS Res Hum Retroviruses 2007; 23:1303-8.
5. Cane P, Chrystie I, Dunn D, et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2005; 331:1368.
6. Fenard D, Lambeau G, Valentin E, Lefebvre JC, Lazdunski M and Doglio A. Secreted phospholipases A(2), a new class of HIV inhibitors that block virus entry into host cells. J Clin Invest 1999; 104:611-8.
7. Zhang YJ, Wang JH, Lee WH, et al. Molecular characterization of Trimeresurus stejnegeri venom L-amino acid oxidase with potential anti-HIV activity. Biochem Biophys Res Commun 2003; 309:598-604.
8. Sillero MA, Madrid O, Zaera E and Sillero A. 2-pm,3′-dideoxynucleoside triphosphates (ddNTP) and di-2′,3′-dideoxynucleoside tetraphosphates (ddN-p4ddN) behave differently to the corresponding NTP and Np4N counterparts as substrates of fire-fly luciferase, dinucleoside tetraphosphatase and phosphodiesterases. Biochim Biophys Acta 1997; 1334:191-9.
9. Hanna Z, Priceputu E, Hu C, Vincent P and Jolicoeur P. HIV-1 Nef mutations abrogating downregulation of CD4 affect other Nef functions and show reduced pathogenicity in transgenic mice. Virology 2006; 346:40-52.
10. Tang S, Murakami T, Cheng N, Steven AC, Freed EO and Levin JG. Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase. J Virology 2003; 77:12592-602.